About Us

T-CURX is a German, venture-backed, private biotechnology company headquartered in Würzburg, Germany, with additional lab space and offices in Munich. T-CURX aims to democratize autologous CAR-T cell therapies by leveraging its proprietary non-viral CAR-T cell technologies for developing in vivo CAR-T and bedside-manufactured CAR-T therapies, to make CAR-T therapies more accessible and affordable for cancer patients. T-CURX’ CAR-T technology is based on T cell-targeted LNP delivery of Sleeping Beauty transposon vectors allowing the generation of stable CAR-expressing CAR-T cells in patients in vivo, in contrast to transient mRNA-based approaches, and without the need for complex, expensive, and immunogenic viral vector systems.

T-CURX was spun out from the academic research group of its co-founder, Prof. Michael Hudecek (MD) - University Hospital of Würzburg, and was co-founded by Prof. Christoph Rader (PhD) (Member of the Scientific Advisory Board) and Ulf Grawunder (PhD), current CEO of the company. Learn more about our team.

Our Pipeline

T-CURX is pursuing development of clinical CAR-T pipeline programs against a novel target in AML and CLL, while two additional follow-on CAR-T pipeline programs target novel cross-entity targets expressed in both hematological malignancies and solid tumor indications. Learn more about our pipeline.

Our Investors

T-CURX is supported by a syndicate of international investors, including BioMedVC as the lead-investor, Highlight Capital, i&iBioFund, and Bayernkapital as co-investors and also by scientific key opinion leaders and life sciences industry veterans with proven track records in developing innovative medicines in the areas of immunology and cancer. Learn more.